CooperVision announced new seven-year findings from its MiSight 1 day contact lens clinical trial.

The 12 months following treatment cessation, mean axial elongation data indicate no evidence of rebound effect, meaning the myopia control gains are retained, the company says.

The research showed the “tremendous potential of MiSight 1 day for children of different ages and with different levels of myopia, regardless of when they start treatment,” says Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator and CooperVision’s director of Research Programs, in a press release.

The company previously reported that MiSight 1 day showed sustained slowing of myopia progression across multiple years of treatment. This was observed in a cohort that wore the lens for the study’s first six years, as well as the original control group who were switched into MiSight for three years.

Abnormal axial length growth slowed by an average of approximately 50% with all tested ages (8 to 17). Trial participants were transitioned from MiSight to a single vision contact lens to evaluate whether treatment gains would be retained. OM